Literature DB >> 368243

Idiopathic paraproteinemia. II. Transplantation of the paraprotein-producing clone from old to young C57BL/KaLwRij mice.

J Radl, E D De Glopper, H R Schuit, C Zurcher.   

Abstract

Transplantation experiments in the C57BL/KaLwRij mouse model of idiopathic paraproteinemia (IP) showed that an IP-producing clone can be further propagated in young, lethally irradiated mice and also equally as well in nonirradiated recipients by a bone marrow and/or spleen cell transfer. The latency period before the original paraprotein was detected in the sera of recipients varied in different experiments between 1 and 9 months after transplantation. With subsequent transplantations, the "take" frequency gradually decreased. Propagation of IP for three to four generations seems to be the final limit. In comparison to age-matched seems to be the final limit. In comparison to age-matched control groups, no substantial influence of the transplanted IP on the survival of the recipients was observed. In contrast, transplantation of cells from mice with a B cell lymphoma or a myeloma led to continuous propagation of the malignancy, with a high "take" frequency, progressive development of the paraproteinemia, and a shortened survival time of the recipients. These findings indicate that IP represents in its final stage in the aging C57BL mice an intrinsic cellular defect within the affected B cell clone, which is, however, different from that found in B cell malignancies.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 368243

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  58 in total

1.  CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma.

Authors:  Sungyoul Hong; Jianfei Qian; Haiyan Li; Jing Yang; Yong Lu; Yuhuan Zheng; Qing Yi
Journal:  Cancer Immunol Immunother       Date:  2011-10-15       Impact factor: 6.968

2.  Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma.

Authors:  Siqing Wang; Jing Yang; Jianfei Qian; Michele Wezeman; Larry W Kwak; Qing Yi
Journal:  Blood       Date:  2005-11-15       Impact factor: 22.113

3.  Bone marrow stromal cells create a permissive microenvironment for myeloma development: a new stromal role for Wnt inhibitor Dkk1.

Authors:  Jessica A Fowler; Gregory R Mundy; Seint T Lwin; Claire M Edwards
Journal:  Cancer Res       Date:  2012-02-28       Impact factor: 12.701

4.  Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells.

Authors:  A Barber; K R Meehan; C L Sentman
Journal:  Gene Ther       Date:  2011-01-06       Impact factor: 5.250

5.  Optimizing dendritic cell vaccine for immunotherapy in multiple myeloma: tumour lysates are more potent tumour antigens than idiotype protein to promote anti-tumour immunity.

Authors:  S Hong; H Li; J Qian; J Yang; Y Lu; Q Yi
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

6.  Idiopathic paraproteinaemia. IV. The role of genetic factors in the development of monoclonal B cell proliferative disorders--a study in the ageing C57BL/KaLwRij and CBA/BrARij mouse radiation chimeras.

Authors:  J Radl; P J Heidt; S Knaan-Shanzer; M J van Zwieten
Journal:  Clin Exp Immunol       Date:  1984-10       Impact factor: 4.330

7.  Autoimmune blood dyscrasias in five patients with hypogammaglobulinemia: response of neutropenia to vincristine.

Authors:  A D Webster; T A Platts-Mills; G Jannossy; M Morgan; G L Asherson
Journal:  J Clin Immunol       Date:  1981-04       Impact factor: 8.317

8.  Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo.

Authors:  Claire M Edwards; Seint T Lwin; Jessica A Fowler; Babatunde O Oyajobi; Junling Zhuang; Andreia L Bates; Gregory R Mundy
Journal:  Am J Hematol       Date:  2009-05       Impact factor: 10.047

9.  Multifunctional role of matrix metalloproteinases in multiple myeloma: a study in the 5T2MM mouse model.

Authors:  Els Van Valckenborgh; Peter I Croucher; Hendrik De Raeve; Chris Carron; Evy De Leenheer; Sylvia Blacher; Laetitia Devy; Agnès Noël; Elke De Bruyne; Kewal Asosingh; Ivan Van Riet; Ben Van Camp; Karin Vanderkerken
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

10.  A murine model of myeloma that allows genetic manipulation of the host microenvironment.

Authors:  Jessica A Fowler; Gregory R Mundy; Seint T Lwin; Conor C Lynch; Claire M Edwards
Journal:  Dis Model Mech       Date:  2009-09-24       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.